Transition Therapeutics Announces Enrollment of the First Patient in Phase 2 Study of ELND005 (Scyllo-inositol) for the Treatment of Agitation/Aggression in Patients with Alzheimer’s Disease

[at noodls] – – Approximately 90% of AD patients develop neuropsychiatric symptoms – Approximately 60% of AD patients develop agitation/aggression TORONTO, ON, November 28th, 2012 – Transition Therapeutics Inc. (Transition … more

View todays social media effects on TTHI

View the latest stocks trending across Twitter. Click to view dashboard